Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Inozyme Pharma, Inc. Banner

Inozyme Pharma, Inc.

INZY Stock Analysis

Page title

Section title

About Inozyme Pharma, Inc.

Biotechnology
Healthcare

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Inozyme Pharma, Inc. Key Metrics

Market Cap
$364M
52 Weeks Low
$2.69
52 Weeks High
$7.80
P/B
3.81x
P/E
-4.06x
P/S
184.46x

Upcoming Events

    INZY Analyst Forecasts

    ‌
    ‌

    INZY Financials

    INZY Income Statement Key Metrics

    • Revenue(TTM)1.98 M
    • Gross Profit(TTM)967,000
    • EBITDA(TTM)-92.40 M
    • Net Income(TTM)-88.56 M
    • EPS Diluted(TTM)-1.46

    Decode INZY's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    INZY earnings and revenue history

    INZY Return on Equity

    See how efficiently INZY generates profit for it's shareholders.

    -50.66%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of INZY (-0.507) is higher than the average of its peers (-0.731).

    Return on Equity Growth

    INZY's Return on Equity has shown poor growth over the past 10 years, increasing by only -0.16%.

    INZY Revenue Growth

    See how INZY has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    INZY's revenue has shown poor growth over the past 10 years, increasing by only 0%.